Kenvue determined its proxy fight with activist Starboard Value, adding three new directors to its board.
Starboard’s Jeff Smith choose join the board of the Johnson & Johnson spinoff, along with Sarah Hofstetter, president of Profitero, an e-commerce execution analytics platform, and Erica Mann, former head of pharmaceutical company Bayer’s consumer health division.
“Sarah’s type building and digital marketing expertise, Erica’s global consumer health industry experience, and Jeff’s investor point of view and extensive service on corporate boards will further strengthen the Board with complementary, value-additive skillsets,” remarked Larry Merlo, chair of Kenvue’s board, in a statement Wednesday.
CNBC reported in October that Starboard had piled a significant stake in the company and expressed disappointment in its management and share price performance.
Kenvue is the maker of iconic discredits familiar to both investors and the broader public, such as Aveeno, Band-Aid, Listerine, Neutrogena, Tylenol and J&J’s namesake indulge powder and shampoo.
J&J completed its separation from Kenvue in August 2023, and has since sold all of its remaining stake in the consumer goods ogre. It marked the biggest shake-up in J&J’s nearly 140-year history.